The long-term outlook to final outcome and steroid treatment results in children with idiopathic nephrotic syndrome. 2015

Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
a Department of Pediatric Nephrology , Ankara Children Health and Research Hematology Oncology Education Research Hospital , Ankara , Turkey .

Idiopathic Nephrotic Syndrome (INS) was defined as combination of a nephrotic syndrome and non-specific histological abnormalities of the kidney. Among these abnormalities, minimal change nephrotic syndrome (MCNS) is the most common. We report our experience with MCNS; its clinical course, treatments and outcomes. One-hundred twenty children (66 male, 54 female) with MCNS, admitted to Nephrology Department between 1987-2009 was assessed. Their clinical presentations, treatment and disease courses were reviewed. The mean duration of follow-up was 11.5 ± 1.9 years. Initially, all patients given prednisone 2 mg/kg/ day single dose per four weeks a followed by eight weeks of the same daily dose given every other day. After week 12, prednisone was progressively tapered off at the rate of 0.5 mg/kg per 15 daily intervals until complete discontinuation had been achieved by week 16. Steroid resistance was accepted as no achievement of remission following four weeks of prednisone 2 mg/kg/day followed by three intravenous pulses of corticosteroids. At the end of the initial steroid treatment, 106 (88.3%) patients were determinate steroid responsive while 14 (11.7%) patients were steroid resistance. Thirty-eight patients underwent biopsy. At the end of study recovery rate was increased from 88.3% to 94.1%. In conclusion, most of patients entered remission by our therapy end of follow up time. With the support of our satisfactory results among the whole study group, long-term prednisolone treatment still remains valid.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D009402 Nephrosis, Lipoid A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA. Glomerulonephritis, Minimal Change,Glomerulopathy, Minimal Change,Nephropathy, Minimal Change,Nephrotic Syndrome, Minimal Change,Idiopathic Minimal Change Nephrotic Syndrome,Minimal Change Disease,Minimal Change Glomerulopathy,Minimal Change Nephrotic Syndrome,Change Diseases, Minimal,Disease, Minimal Change,Diseases, Minimal Change,Glomerulonephritides, Minimal Change,Glomerulopathies, Minimal Change,Lipoid Nephroses,Lipoid Nephrosis,Minimal Change Diseases,Minimal Change Glomerulonephritides,Minimal Change Glomerulonephritis,Minimal Change Nephropathies,Minimal Change Nephropathy,Nephropathies, Minimal Change,Nephroses, Lipoid
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
October 2009, Clinical journal of the American Society of Nephrology : CJASN,
Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
March 2016, Pediatric nephrology (Berlin, Germany),
Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
March 2016, Pediatric nephrology (Berlin, Germany),
Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
June 1969, The American journal of medicine,
Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
October 2017, Journal of the American Society of Nephrology : JASN,
Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
August 2009, Pediatric nephrology (Berlin, Germany),
Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
June 1993, Pediatric nephrology (Berlin, Germany),
Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
April 2018, Nephrologie & therapeutique,
Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
August 2005, The Journal of pediatrics,
Nida Dinçel, and Ebru Yılmaz, and İpek Kaplan Bulut, and Şükriye Hacıkara, and Sevgi Mir
June 2013, Pediatric nephrology (Berlin, Germany),
Copied contents to your clipboard!